CART 19/22 T CELLS for Acute lymphoblastic leukemia (B-cell, relapsed/refractory) | Acute lymphoblastic leukemia (T-cell, relapsed/refractory)

Inclusion criteria

• {"criterion_text":"- Age: Patients <30 years at diagnosis and/or relapse."}
• {"criterion_text":"- Lansky (age <16 years) or Karnofsky (age ≥16 years) score of 50 or greater."}
• {"criterion_text":"- Life expectancy greater than 12 weeks."}
• {"criterion_text":"- Absolute neutrophil count (ANC) ≥ 500/μL unless, in the opinion of the investigator, cytopenia is due to underlying leukemia and is potentially reversible with leukemia therapy."}
• {"criterion_text":"- Platelet count ≥ 50,000/μL unless, in the opinion of the investigator, cytopenia is due to underlying leukemia and is potentially reversible with leukemia therapy."}
• {"criterion_text":"- Absolute lymphocyte count ≥ 100/μL."}
• {"criterion_text":"- Adequate renal, hepatic, pulmonary, and cardiac function."}
• {"criterion_text":"- Adequate venous access and absence of contraindications for lymphoapheresis."}
• {"criterion_text":"- Patients with a seizure disorder may be enrolled if well controlled with anticonvulsants."}
• {"criterion_text":"- Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent."}
• {"criterion_text":"- Diagnosis: o ARM A: CD19+/- CD22+ B-ALL with relapsed or refractory disease not responding to conventional chemotherapy and with no other curative therapy available. Treatment with previous CART CD19 therapy is permitted, but is not mandatory. / o\tARM B: T-ALL with relapsed or refractory disease not responding to conventional chemotherapy and with no other curative therapy available."}
• {"criterion_text":"- Patients diagnosed with ALL must be suitable for allogeneic HSCT and willing to proceed to transplant if the CART treatment induces complete remission and the investigator believes it is the best option."}
• {"criterion_text":"- For ARM B there must be a suitable haploidentical donor (following local SOP)."}

Exclusion criteria

• {"criterion_text":"- Enrolled in another clinical trial in the previous 4 weeks."}
• {"criterion_text":"- Active infection requiring systemic medical therapy including clinically significant viral infection or uncontrolled viral reactivation of EBV, CMV, adenovirus, BK-virus, HHV-6 or Aspergillus."}
• {"criterion_text":"- Any of the following cardiac criteria: cardiac echocardiography with LVSF<30% or LVEF<40%; or clinically significant pericardial effusion."}
• {"criterion_text":"- Presence of CNS-3 disease or uncontrolled seizure disorder."}
• {"criterion_text":"- Active immunosuppressive therapy with the exception of prednisone 10 mg/day (or equivalent), within 7 days prior to enrolment."}
• {"criterion_text":"- GFR <30 ml/min or bilirubin >3 times the upper limit of normality (unless due to Gilbert's syndrome)."}
• {"criterion_text":"- Any other condition that, in the opinion of the PI, may interfere with the efficacy and/or safety evaluation of the trial."}
• {"criterion_text":"- Pregnant or lactating women."}
• {"criterion_text":"- Sexually active patients must be willing to utilize one of the more effective birth control methods for at least 12 months after the infusion and until CAR-T cells are no longer present on two consecutive tests. Male partner should use a condom. Women of child-bearing potential are defined as all women physiologically capable of becoming pregnant. Highly effective contraception methods include, as defined by the CTFG recommendations (available at h t t p s : / / w w w . h m a . e u / f i l e a d m i n / d a t e i e n / H u m a n _ M e d i c i n e s / 0 1 -About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf): o\tCombined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) o\t Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) o\tIntrauterine device (IUD) o\tIntrauterine hormone-releasing system o\tBilateral tubal occlusion o\tVasectomized partner (provided that partner is the sole sexual partner of the trial participant and that the vasectomized partner has received medical assessment of the surgical success) o\tSexual abstinence (only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject). Sexually active males should use a condom during intercourse for at least 12 months after the infusion and until CAR-T cells are no longer present on two consecutive tests."}

Primary endpoints

• {"endpoint_text":"- In this umbrella trial, we will determine in parallel within independent cohorts: 1- The safety and feasibility of autologous CART-19/22 in children, adolescents and young adults with a CD19+/- CD22+ relapse/ refractory disease for a r/r B-ALL. 2- The safety and feasibility of allogeneic CART-NKG2D T in children, adolescents and young adults with r/r T-ALL.","definition_or_measurement_approach":"Not specified beyond the stated objective of assessing 'safety and feasibility' within the independent cohorts."}

Secondary endpoints

• {"endpoint_text":"- Expression of CD19/CD22 and NKG2DL on primary B- or T- cell ALL, respectively.","definition_or_measurement_approach":"Assessment of antigen expression on primary leukemia samples (method not specified)."}
• {"endpoint_text":"- Persistence of CART19/22 and CARTs-NKG2D cells in patients’ samples (peripheral blood, bone marrow, cerebrospinal fluid).","definition_or_measurement_approach":"Measured in patient samples: peripheral blood, bone marrow, and cerebrospinal fluid (sampling and assay methods not specified)."}
• {"endpoint_text":"- Peripheral blood cytokine profile from the patients’ serum.","definition_or_measurement_approach":"Weekly serum cytokine profiling until evaluation (assay specifics not provided)."}
• {"endpoint_text":"- Identify the DNA methylation profile of NKG2DL (MICA, MICB AND ULBPs 1-3) in primary T-cell malignancies’ samples.","definition_or_measurement_approach":"DNA methylation profiling of specified genes in primary T-cell malignancy samples (methods not specified)."}
• {"endpoint_text":"- Evaluate the presence of soluble NKG2DL and ANTI-MICA and ANTI-MICB antibodies in the serum of patients under CART-NKG2D therapy.","definition_or_measurement_approach":"Serologic assessment for soluble NKG2DL and anti-MICA/anti-MICB antibodies (methods not specified)."}
• {"endpoint_text":"- Overall rate response in both arms.","definition_or_measurement_approach":"Overall response rate assessment (response criteria not specified in the available text)."}

Spain

Earliest CTIS Part Ii Submission Date

25-10-2024

Latest Decision Or Authorization Date

29-09-2025

Processing Time Days

339

Number Of Sites

1

Number Of Participants

10

Primary sponsor

Full Name

Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz

Organisation Type

Patient organisation/association

Country Of Registered Address

Spain